VCEL Overview

Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full-thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adult and pediatric patients with deep partial thickness and/or full-thickness thermal burns.

Wall Street analysts forecast VCEL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VCEL is57.67 USD with a low forecast of 55.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Vericel Corp revenue for the last quarter amounts to 92.92M USD, increased 23.27

Vericel Corp. EPS for the last quarter amounts to 0.40 USD, increased 21.21

Vericel Corp (VCEL) has 398 emplpoyees as of April 15 2026.

Today VCEL has the market capitalization of 1.79B USD.